Although the gene products of ATM, CHEK2 and ERBB2 are involved in various aspects of breast cancer development and progression, our results suggest that common variation in these genes does not affect survival, tumour-characteristic-defined risk or the overall risk of breast cancer. This evidence concerns the gene CHEK2 and neoplasm.